GlassScriptPhysician profile
Kari M Self
NPI 1124552989
$3,416.04
in general payments reported to CMS, 2019-2025
25 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $311 · 2023: $1,174 · 2024: $1,220 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,729.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $537.40 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $404.58 | 2021-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.18 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $342.69 | 2021-2024 | |
| Abbott Laboratories | $266.02 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Daiichi Sankyo INC. | $193.93 | 2021-2024 | Injectafer |
| Pfizer INC. | $179.27 | 2021-2024 | |
| Cvrx, INC. | $164.59 | 2024 | Barostim Neo System |
| Atricure, INC. | $148.49 | 2024 | |
| Janssen Pharmaceuticals, INC | $97.00 | 2021-2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $92.46 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $92.07 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $80.00 | 2023-2025 | Eliquis, Camzyos |
| Inspire Medical Systems, INC. | $67.45 | 2024-2025 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $59.53 | 2023 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $56.91 | 2023-2025 | |
| Daxor Corporation | $45.51 | 2023 | Bva-100 |
| Novo Nordisk INC | $45.08 | 2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $44.90 | 2023-2024 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $43.57 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $40.62 | 2023 | |
| Heartflow, INC. | $19.53 | 2024 | |
| Alnylam Pharmaceuticals INC. | $18.36 | 2023 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $17.27 | 2024 | |
| Amgen INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Self listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.